Volibo R 0.3/0.5 mg
| SKU | 2607 |
|---|---|
| Generic For | Voglibose R |
| Manufacturer | Ajanta Pharma India |
| Active Ingredient | Voglibose / Repaglinide |
| Pack Size | Qty | Price Per Pill or Unit | Price | Cart | |
|---|---|---|---|---|---|
| 30 Tablet/s | US$ 0.79 | US$ 23.70 | |||
|
|||||
| 60 Tablet/s | US$ 0.71 | US$ 42.6610%US$ 47.40 | |||
|
|||||
| 90 Tablet/s | US$ 0.67 | US$ 60.4415%US$ 71.10 | |||
|
|||||
Volibo R 0.3/0.5 mg – Affordable Voglibose R Alternative
Volibo R 0.3/0.5 mg is a fixed-dose combination medicine containing voglibose and repaglinide. It is prescribed to control high blood sugar levels after each meal. Volibo R is used when other similar medicines and a restricted diet can’t control abnormally high sugar levels in patients with Type 2 diabetes.
Type 2 diabetes is characterized by insulin resistance and progressive pancreatic beta cell function decline associated with increased blood sugar. The net result is that more glucose (sugar) enters the circulation faster than the body can remove it, resulting in prolonged elevation of blood glucose.
Voglibose is an alpha-glucosidase inhibitor that provides another therapeutic option for patients with type 2 diabetes whose glycaemic control is inadequate, despite diet alone or with pharmacological therapy with sulfonylurea and biguanide. Repaglinide helps the body to release more insulin. The combination drug is effective in treating elderly patients and in those with mild to moderate kidney function impairment when other antidiabetic agents are ineffective.
Before taking Volibo R tablets, tell your doctor if you develop kidney problems, liver disease, urinary tract infections, or are on water pills. Pregnant and breastfeeding women should consult their doctor before taking it. Your driving ability may be affected if your blood sugar is too low or too high. Avoid driving if you develop these symptoms. Be sure to tell your doctor about all your products, including prescription, non-prescription, and herbal products.
The most reported side effects of Volibo R 0.3/0.5 mg include diarrhea, flatulence, low blood sugar, and skin rash. However, most of these side effects are temporary and usually resolve on their own. Please talk to your doctor if they become troublesome or persist for a long time. Avoid excessive alcohol intake while receiving this antidiabetic agent, as it may increase the risk of developing some side effects.
Volibo R 0.3/0.5 mg should be taken as prescribed; your doctor will decide the dose and duration. Do not stop treatment without your doctor’s approval. If you do so, your blood sugar levels may increase, making you more likely to get serious complications like blindness and kidney damage. This fixed-dose combination drug is a part of the treatment program that should include a healthy diet, regular exercise, healthy diet, regular exercise, and weight reduction as instructed by the doctor.
Keep a check on your blood sugar levels. Tracking and sharing the results with your doctor is important to determine the correct dose. Tell him if your blood sugar levels are too high or too low, he may change the treatment accordingly.
What is Volibo R 0.3/0.5 mg and what condition does it treat?
Volibo R 0.3/0.5 mg is a combination antidiabetic medication containing two active ingredients: voglibose and repaglinide. This dual-action diabetes medicine is prescribed to manage type 2 diabetes mellitus in adults. Voglibose belongs to the alpha-glucosidase inhibitor class, while repaglinide is a meglitinide antidiabetic agent. Together, these components work synergistically to control blood sugar levels after meals and throughout the day. This combination therapy is particularly beneficial for patients who require both post-meal glucose control and insulin secretion support. Volibo R helps reduce HbA1c levels and minimizes diabetes complications when used alongside proper diet and exercise.
How does Volibo R 0.3/0.5 mg work to control blood sugar?
Volibo R 0.3/0.5 mg employs a dual mechanism to manage type 2 diabetes effectively. The voglibose component inhibits alpha-glucosidase enzymes in your intestinal walls, slowing down carbohydrate breakdown and preventing rapid glucose absorption after eating. This reduces post-meal blood sugar spikes significantly. Meanwhile, the repaglinide component stimulates your pancreas to release insulin quickly in response to meals, addressing immediate glucose elevation. This meglitinide works rapidly and has a shorter duration compared to sulfonylureas. The combination provides comprehensive glycemic control by targeting both glucose absorption and insulin secretion pathways, making this antidiabetic therapy more effective than single-agent treatments for many patients.
How long does Volibo R 0.3/0.5 mg take to start working?
Volibo R 0.3/0.5 mg begins working relatively quickly after ingestion. The repaglinide component starts stimulating insulin release within 15-30 minutes, with peak effects occurring around one hour after taking the tablet. This rapid action makes it effective for controlling post-meal glucose surges. The voglibose component starts inhibiting carbohydrate digestion immediately upon reaching your intestines. However, noticeable improvements in overall blood sugar control typically become evident after several days of consistent use. Maximum therapeutic benefits, including reductions in fasting glucose and HbA1c levels, usually appear after 2-3 months of regular treatment combined with appropriate lifestyle modifications.
When and how should I take Volibo R 0.3/0.5 mg for best results?
Take Volibo R 0.3/0.5 mg immediately before meals, ideally within 15 minutes of eating. This timing is crucial because the repaglinide component works by stimulating insulin release in response to food intake. The medication is typically prescribed two to three times daily, depending on your meal pattern. Swallow the tablet whole with water—do not crush or chew it. If you skip a meal, skip that dose to avoid hypoglycemia risk. Consistency is important for optimal diabetes control. Your healthcare provider will determine the appropriate dosing schedule based on your blood glucose monitoring results, dietary habits, and overall treatment goals.
Is Volibo R 0.3/0.5 mg safe for long-term diabetes management?
Volibo R 0.3/0.5 mg is generally considered safe for extended use in managing type 2 diabetes when taken as prescribed. Many patients use this combination antidiabetic medication for years with regular medical monitoring. Long-term safety involves periodic blood glucose checks, HbA1c testing every 3-6 months, and liver function assessments as recommended by your doctor. The voglibose and repaglinide combination has been studied extensively for chronic diabetes treatment. Maintaining proper dosing, following dietary recommendations, and attending regular check-ups help ensure continued safety. Your healthcare provider will adjust treatment if needed based on your response, tolerability, and any changes in your overall health status.
Can I take Volibo R 0.3/0.5 mg with my other medications?
Volibo R 0.3/0.5 mg can interact with various medications, so disclosure of all drugs you're taking is essential. Beta-blockers may mask hypoglycemia symptoms, while certain antibiotics and antifungals can increase repaglinide levels. Corticosteroids and thiazide diuretics may reduce this diabetes medicine's effectiveness. Gemfibrozil significantly increases repaglinide concentrations and should typically be avoided. Other antidiabetic medications may require dose adjustments to prevent excessive blood sugar lowering. Herbal supplements, particularly those affecting glucose metabolism, warrant discussion. Always inform healthcare providers about this combination therapy before starting new prescriptions. A comprehensive medication review ensures safe, effective diabetes management without harmful drug interactions.
How does Volibo R 0.3/0.5 mg compare to other diabetes medications?
Volibo R 0.3/0.5 mg offers distinct advantages through its dual-action approach compared to single-agent diabetes treatments. Unlike metformin alone, which primarily reduces glucose production, this combination addresses both absorption and insulin secretion. Compared to sulfonylureas, the repaglinide component has shorter action with lower hypoglycemia risk when meals are skipped. The voglibose element provides post-meal control similar to acarbose but may have better tolerability for some patients. This combination therapy often achieves superior HbA1c reductions compared to monotherapy. However, it requires multiple daily doses unlike once-daily options such as DPP-4 inhibitors. Your diabetes specialist will determine if this antidiabetic medication suits your specific glycemic pattern and lifestyle.
Is generic voglibose-repaglinide as effective as branded Volibo R?
Generic voglibose-repaglinide combinations are therapeutically equivalent to branded Volibo R 0.3/0.5 mg when manufactured to proper pharmaceutical standards. Both contain identical active ingredients in the same strengths and must meet stringent bioequivalence requirements set by regulatory authorities. Generic versions deliver the same blood sugar control, safety profile, and clinical outcomes as the brand-name diabetes medication. The primary differences involve inactive ingredients, packaging, and cost—generics typically offer significant savings. When sourced from reputable manufacturers and licensed pharmacies, generic antidiabetic medications provide reliable, effective type 2 diabetes management. Quality-assured generics make this important combination therapy more accessible and affordable for long-term treatment.
Why do patients trust PremiumRxDrugs for Volibo R 0.3/0.5 mg?
Patients consistently choose PremiumRxDrugs for their Volibo R 0.3/0.5 mg because of the pharmacy's commitment to authenticity, affordability, and service excellence. As a licensed pharmacy with more than ten years of trusted operation, we guarantee manufacturer-sourced, genuine diabetes medications at competitive prices. Our worldwide shipping reaches patients in the USA, UK, Australia, Canada, and beyond, with free shipping options available. Discreet packaging protects your privacy while convenient prescription management and easy reordering simplify chronic diabetes treatment. The platform offers both branded Volibo R and generic voglibose-repaglinide alternatives, providing cost-effective options without compromising quality. This combination of reliability, value, and comprehensive service makes PremiumRxDrugs a preferred source.
What are the common side effects of voglibose and repaglinide?
Common side effects of voglibose and repaglinide include gastrointestinal symptoms such as flatulence, abdominal discomfort, bloating, and diarrhea, primarily from the voglibose component slowing carbohydrate digestion. Hypoglycemia (low blood sugar) can occur with repaglinide, especially if meals are delayed or skipped, causing symptoms like shakiness, sweating, dizziness, and hunger. Some patients experience mild nausea or headaches during initial treatment. Weight gain may occur with repaglinide use due to improved glucose utilization. These antidiabetic medication side effects often diminish as your body adjusts. Severe reactions are uncommon but include allergic responses or significant hypoglycemia requiring immediate attention. Monitoring blood glucose regularly helps identify and manage potential issues effectively.
Who should avoid taking voglibose and repaglinide for diabetes?
Voglibose and repaglinide are contraindicated in several situations. Individuals with type 1 diabetes or diabetic ketoacidosis should not use this combination as insulin is required. Those with severe liver impairment cannot safely metabolize repaglinide. Patients with inflammatory bowel disease, intestinal obstruction, or chronic digestive disorders should avoid voglibose due to gastrointestinal effects. This antidiabetic combination is not suitable during pregnancy or breastfeeding. People with known hypersensitivity to either active ingredient should seek alternatives. Those taking gemfibrozil should typically avoid repaglinide due to significant interaction risks. Children and adolescents lack established safety data for this medication. Your healthcare provider will assess your complete medical history to determine appropriate diabetes treatment options.
Login
Sign Up
Login
Sign Up